Overview

A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Status:
Completed
Trial end date:
2011-07-21
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Rituximab